Patent infringement claim dismissed because generic escitalopram sale did not violate the specific method patent rights.

The Court of Appeal dismissed the appeal against the City Court's decision prohibiting Rekvisitus A/S from marketing generic escitalopram. Rekvisitus argued that selling the generic drug infringed Rekvirent A/S's rights under a method patent, while Rekvirent contended the sale constituted unauthorized use of the patented process. The court ruled that selling the finished product does not infringe a method patent unless the product itself is the result of the patented method, which was not established here.